American Academy of Neurology presentation tomorrow is the next significant catalyst
Full -020 data set will be revealed tomorrow (March 20, 2013) at the AAON meeting (Antipsychotic efficacy and motor tolerability in a Phase III placebo-controlled study of pimavanserin in patients with Parkinson’s disease psychosis (ACP-103-020)) and presented by Jeffrey Cummings, MD, FAAN.
Recall at last weeks earnings call, Acadia's VP of Development stated "I'm pleased to report that we've now completed our analysis of the full -020 data set, and have continued to see consistent and robust data aligned with the top line efficacy results. The -020 shows highly significant improvements on both the primary and secondary antipsychotic efficacy endpoints. Significant improvements were also demonstrated on nighttime sleep and daytime wakefulness and on caregiver burden. In addition, the key secondary endpoint of motoric tolerability was met, and the overall safety profile of pimavanserin continued to appear benign."
This is the next stage of the rocket poised to boost shares from current levels - and the very reason Jefferies got in ahead of the curve in upgrading ACAD shares to $13 today.